CAR-T immunotherapy: how will it change treatment for acute lymphoblastic leukemia and beyond?
Open accessAbstract
INTRODUCTION: The recent approval of CD19 chimeric antigen receptor (CAR) T cells for refractory or second relapse of B cell acute lymphoblastic leukemia (B-ALL) has led to a paradigm shift. Besides being an alternative to chemotherapy and antibody-based approaches, CAR-T cells have become the first successful example of "personalized medicine." AREAS COVERED: In clinical trials, tisagenlecleucel demonstrated higher response rates than prior therapies, and led to durable remissions lasting up to years for some children. Toxicities like cytokine release syndrome and neurotoxicity, while potentially reversible, have limited usage of CAR-T cells at certified centers with expertise in cellular therapy. Strategies to deal with B-ALL relapse after CAR-T remain an open area of research. EXPERT OPINION: Going forward, improvements will likely be seen in managing the side effects of CAR-T therapy as well as usage of CAR-T cells upfront as a replacement for chemotherapy or allogeneic bone marrow transplant for B-ALL. Further advances will need to reduce the biomanufacturing time needed to generate CAR-T cells as well as develop biomarkers that predict CAR-T persistence and/or toxicities.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Most Investigator Brochures and the product insert of ZOLGENSMA recommend 30-day universal or standard precautions.
“Most of the Investigator Brochures and also the product insert of ZOLGENSMA recommend 30-day universal or standard precautions.126,128”
From Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges (2020) · cites this paper as [128]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735 · see citing works
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · see citing works
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · see citing works
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815 · see citing works
Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406 · see citing works
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler‐Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P. L., Martin, S. C., Delbrook, C., Yates, B., et al. (2017) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,336 · see citing works
Santomasso, B. D., Park, J. H., Salloum, D., Riviere, I., Flynn, J., Mead, E., Halton, E., Wang, X., Senechal, B., Purdon, T., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1319 · Cited by 942 · see citing works
von Stackelberg, A., Locatelli, F., Zugmaier, G., Handgretinger, R., Trippett, T. M., Rizzari, C., Bader, P., O'Brien, M. M., Brethon, B., Bhojwani, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3301 · Cited by 614 · see citing works
Nguyen, K., Devidas, M., Sc, C., La, M., Raetz, E. A., Carroll, W. L., Winick, N. J., Hunger, S. P., Gaynon, P. S., Loh, M. L., et al. (2008) · Leukemia · doi:10.1038/leu.2008.251 · Cited by 584 · see citing works
Kantarjian, H. M., Thomas, D. A., Jorgensen, J. L., Jabbour, E. J., Kebriaei, P., Rytting, M., York, S., Ravandi, F., Kwari, M. I., Faderl, S. H., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70386-2 · Cited by 411 · see citing works
Parker, C. A., Waters, R., Leighton, C., Hancock, J. P., Sutton, R., Moorman, A. V., Ancliff, P., Morgan, M. A. M., Masurekar, A. N., Goulden, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62002-8 · Cited by 331 · see citing works
Tallen, G. R. N., Ratei, R., Mann, G., Kaspers, G. J. L., Niggli, F. K., Karachunskiy, A. I., Ebell, W., Escherich, G., Schrappe, M., Klingebiel, T. E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1983 · Cited by 307 · see citing works
von Stackelberg, A., Völzke, E., Kühl, J., Seeger, K., Schrauder, A., Escherich, G., Henze, G., & Tallen, G. R. N. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.09.020 · Cited by 98 · see citing works
Bioengineering Solutions for Manufacturing Challenges in CAR T Cells
Piscopo, N. J., Mueller, K. P., Das, A., Hematti, P., Murphy, W. L., Palecek, S. P., Capitini, C. M., & Saha, K. (2017) · Biotechnology Journal · doi:10.1002/biot.201700095 · Cited by 86 · see citing works
Self-citationEapen, M., Zhang, M.-J., Devidas, M., Raetz, E. A., Barredo, J. C., Ritchey, A. K., Godder, K. T., Grupp, S. A., Lewis, V. A., Malloy, K., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2405037 · Cited by 58 · see citing works
Harker-Murray, P. D., Thomas, A. J., Wagner, J. E., Weisdorf, D. J., Luo, X., DeFor, T. E., Verneris, M. R., Dusenbery, K. E., MacMillan, M. L., Tolar, J., et al. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.03.011 · Cited by 29 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Ghosh, S., Brown, A. M., Jenkins, C., & Campbell, K. (2020) · Applied Biosafety · doi:10.1177/1535676019899502 · Cited by 218 · see citing works
A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL
Zanetti, S. R., Velasco-Hernández, T., Gutiérrez‐Agüera, F., Diaz, V. M., Romecín, P. A., Roca-Ho, H., Sánchez‐Martínez, D., Tirado, N., Baroni, M. L., Petazzi, P., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.033 · Cited by 48 · see citing works
Bueno, C., Barrera, S., Bataller, Á., Ortiz‐Maldonado, V., Elliott, N., O’Byrne, S., Wang, G., Rovira, M., Gutiérrez‐Agüera, F., Trincado, J. L., et al. (2022) · Blood · doi:10.1182/blood.2021014840 · Cited by 39 · see citing works
Falgàs, A., Lázaro‐Gorines, R., Zanetti, S. R., Rubio-Pérez, L., Martínez-Moreno, A., Vinyoles, M., Guerrero-Murillo, M., Fernández‐Fuentes, N., Roca-Ho, H., Tirado, N., et al. (2025) · Blood · doi:10.1182/blood.2024025440 · Cited by 21 · see citing works
Immunotherapies for Childhood CancerPreprint
Park, J. A., & Cheung, N. V. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041574 · Cited by 10 · see citing works
Novel therapies for childhood cancer and impact on puberty
Wei, C. H., Stevens, M. C. G., & Crowne, E. C. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.06.010 · Cited by 1 · see citing works
Transforming Institutions from “Sickcare” to Longevity
Hudgins, E. (2026) · Healthy ageing and longevity · doi:10.1007/978-3-032-20006-8_23
- Authors
- Capitini, C. M.
- Affiliations
- University of Wisconsin–Madison (US)
- Corresponding author
- Capitini, Christian M.
- Venue
- Expert Opinion on Orphan Drugs
- Publisher
- Informa UK Limited
- Published
- 2018-10-03
- Volume
- 6
- Issue
- 10
- Pages
- 563-566
- ISSN
- 2167-8707 (ISSN-L)
- PMC
- PMC6375487
- OpenAlex
- W2893169522
- Cited by
- 7
- References
- 16
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2022: 1 · 2021: 1 · 2020: 2
- FWCI
- 0.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Expert Opinion on Orphan Drugs (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (K08 CA174750, P30 CA014520)
- National Science Foundation (EAGER CBET-1645123)
- Stand Up To Cancer (SU2C-AACR-DT1113)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CAR-T immunotherapy, B-cell acute lymphoblastic leukemia, CD19 chimeric antigen receptor, tisagenlecleucel, cytokine release syndrome, neurotoxicity, relapsed/refractory leukemia, personalized medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
